Short Interest Alert: What’s CYTODYN INCORPORATED (OTCMKTS:CYDY) Upside After This Short Interest Decrease?

November 30, 2016 - By Pete Kolinski   ·   0 Comments

Short Interest Alert: What's CYTODYN INCORPORATED (OTCMKTS:CYDY) Upside After This Short Interest Decrease?

The stock of CYTODYN INCORPORATED (OTCMKTS:CYDY) registered a decrease of 40% in short interest. CYDY’s total short interest was 58,800 shares in November as published by FINRA. Its down 40% from 98,000 shares, reported previously. With 582,000 shares average volume, it will take short sellers 0 days to cover their CYDY’s short positions. The stock last traded at $0.66 per share. It is down 43.59% since April 27, 2016 and is downtrending. It has underperformed by 48.82% the S&P500.

CytoDyn Inc. is a clinical-stage biotechnology company. The company has a market cap of $90.95 million. The Firm is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus infection. It currently has negative earnings. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

CYDY Company Profile

CytoDyn Inc., incorporated on May 2, 2002, is a clinical-stage biotechnology company. The Firm is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company’s product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection.

Another recent and important CytoDyn Inc (OTCMKTS:CYDY) news was published by Marketwatch.com which published an article titled: “CytoDyn Inc.” on April 14, 2011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Pete Kolinski


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>